Published on 29 Mar 2023 on The Business Journals
Diabetes drug developer Biomea Fusion seeks $125 million - San Francisco Business Times
Strong diabetes drug trial pushes $BMEA to target $125 million stock sale
NASDAQ.BMEA price evolution
NASDAQ.FUSN price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free